This content is machine translated Cutaneous lupus erythematosus (CLE) Assessment and outlook An overview article published in 2023 summarizes current and potential future treatment strategies for CLE. It remains to be seen whether further progress in researching the pathogenetic relationships will bring…
View Post 4 min This content is machine translated Systemic lupus erythematosus The future belongs to precision medicine The multiple disease manifestations of systemic lupus erythematosus (SLE) are essentially a consequence of autoantibodies, immune complexes, and cytokines. New therapies specifically intervene in the immunopathogenesis of the complex autoimmune…
View Post 6 min This content is machine translated Systemic lupus erythematosus What can belimumab and anifrolumab do? The monoclonal antibodies belimumab and anifrolumab are both approved for the treatment of systemic lupus erythematosus (SLE). Their response is considered to be highly effective. The point at which they…
View Post 5 min This content is machine translated Systemic lupus erythematosus (SLE) Anifrolumab: 3-year data confirm long-term clinical benefit New data from a long-term extension study show that anifrolumab was effective, safe, and tolerable in systemic lupus erythematosus (SLE) even in long-term use over three years [1]. Two post-hoc…
